Over the past couple of decades considerable progress has been made in the management of metastatic colorectal cancers(mCRC) leading to a significant improvement in five-year survival. Although part of this success ha...Over the past couple of decades considerable progress has been made in the management of metastatic colorectal cancers(mCRC) leading to a significant improvement in five-year survival. Although part of this success has been rightly attributed to aggressive surgical management and advances in other adjunct treatments, our understanding of the pathogenesis of cancer and emergence of newer molecular targets for colon cancer has created a powerful impact. In this review article we will discuss various targeted therapies in the management of mCRC. Newer agents on the horizon soon to be incorporated in clinical practice will be briefly reviewed as well.展开更多
目的研究我院新型抗肿瘤药物引起的药品不良反应(adverse drug reaction,ADR)发生特点及规律,为临床合理用药提供参考。方法收集我院2020年1月1日至2021年12月31日上报至国家药品不良反应监测系统的新型抗肿瘤药物ADR,对ADR类型、患者...目的研究我院新型抗肿瘤药物引起的药品不良反应(adverse drug reaction,ADR)发生特点及规律,为临床合理用药提供参考。方法收集我院2020年1月1日至2021年12月31日上报至国家药品不良反应监测系统的新型抗肿瘤药物ADR,对ADR类型、患者年龄和疾病类型、药品种类、累及系统-器官、严重ADR的主要药品及临床表现等方面进行分析。结果84例新型抗肿瘤药物ADR中,中老年患者居多;累及系统-器官主要是消化系统和皮肤及其附件系统;严重ADR占比34.52%。9例患者存在超说明书用药的问题。结论临床医师和药师应重视新型抗肿瘤药物致ADR,加强患者药学监护,为临床用药安全以及药品上市后再评价提供参考依据。展开更多
文摘Over the past couple of decades considerable progress has been made in the management of metastatic colorectal cancers(mCRC) leading to a significant improvement in five-year survival. Although part of this success has been rightly attributed to aggressive surgical management and advances in other adjunct treatments, our understanding of the pathogenesis of cancer and emergence of newer molecular targets for colon cancer has created a powerful impact. In this review article we will discuss various targeted therapies in the management of mCRC. Newer agents on the horizon soon to be incorporated in clinical practice will be briefly reviewed as well.
文摘目的研究我院新型抗肿瘤药物引起的药品不良反应(adverse drug reaction,ADR)发生特点及规律,为临床合理用药提供参考。方法收集我院2020年1月1日至2021年12月31日上报至国家药品不良反应监测系统的新型抗肿瘤药物ADR,对ADR类型、患者年龄和疾病类型、药品种类、累及系统-器官、严重ADR的主要药品及临床表现等方面进行分析。结果84例新型抗肿瘤药物ADR中,中老年患者居多;累及系统-器官主要是消化系统和皮肤及其附件系统;严重ADR占比34.52%。9例患者存在超说明书用药的问题。结论临床医师和药师应重视新型抗肿瘤药物致ADR,加强患者药学监护,为临床用药安全以及药品上市后再评价提供参考依据。